266 related articles for article (PubMed ID: 29866617)
1. Quadrivalent influenza vaccines in low and middle income countries: Cost-effectiveness, affordability and availability.
Hendriks J; Hutubessy RCW; Grohmann G; Torelli G; Friede M; Kieny MP
Vaccine; 2018 Jun; 36(28):3993-3997. PubMed ID: 29866617
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.
de Boer PT; Kelso JK; Halder N; Nguyen TP; Moyes J; Cohen C; Barr IG; Postma MJ; Milne GJ
Vaccine; 2018 Feb; 36(7):997-1007. PubMed ID: 29373192
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
de Boer PT; Crépey P; Pitman RJ; Macabeo B; Chit A; Postma MJ
Value Health; 2016 Dec; 19(8):964-975. PubMed ID: 27987647
[TBL] [Abstract][Full Text] [Related]
5. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China.
Jiang M; Li P; Wang W; Zhao M; Atif N; Zhu S; Fang Y
Vaccine; 2020 Jan; 38(5):1057-1064. PubMed ID: 31787414
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
Yang MC; Tan EC; Su JJ
Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
García A; Ortiz de Lejarazu R; Reina J; Callejo D; Cuervo J; Morano Larragueta R
Hum Vaccin Immunother; 2016 Sep; 12(9):2269-77. PubMed ID: 27184622
[TBL] [Abstract][Full Text] [Related]
9. From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain.
Crépey P; Redondo E; Díez-Domingo J; Ortiz de Lejarazu R; Martinón-Torres F; Gil de Miguel Á; López-Belmonte JL; Alvarez FP; Bricout H; Solozabal M
PLoS One; 2020; 15(5):e0233526. PubMed ID: 32437476
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population.
Capri S; Barbieri M; de Waure C; Boccalini S; Panatto D
Hum Vaccin Immunother; 2018 Jun; 14(6):1331-1341. PubMed ID: 29425079
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.
Mennini FS; Bini C; Marcellusi A; Rinaldi A; Franco E
Hum Vaccin Immunother; 2018; 14(8):1867-1873. PubMed ID: 29708843
[TBL] [Abstract][Full Text] [Related]
12. Cost Utility of Switching From Trivalent to Quadrivalent Influenza Vaccine in Turkey.
Amiche A; Tanriover MD; Bellier L; Ugur B; Akin L
Value Health Reg Issues; 2021 Sep; 25():15-22. PubMed ID: 33485248
[TBL] [Abstract][Full Text] [Related]
13. Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay.
Arbo A; Martinez-Cuellar C; Vazquez C; Bellier L; Adorno C; Dibarboure H; Lopez JG; Petitjean A; Bianculli P
Hum Vaccin Immunother; 2022 Nov; 18(5):2069974. PubMed ID: 35543602
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis.
You JH; Ming WK; Chan PK
Hum Vaccin Immunother; 2015; 11(3):564-71. PubMed ID: 25714506
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.
Beran J; Peeters M; Dewé W; Raupachová J; Hobzová L; Devaster JM
BMC Infect Dis; 2013 May; 13():224. PubMed ID: 23688546
[TBL] [Abstract][Full Text] [Related]
16. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe.
Uhart M; Bricout H; Clay E; Largeron N
Hum Vaccin Immunother; 2016 Sep; 12(9):2259-68. PubMed ID: 27166916
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of the health economic consequences of quadrivalent influenza vaccination.
de Boer PT; van Maanen BM; Damm O; Ultsch B; Dolk FCK; Crépey P; Pitman R; Wilschut JC; Postma MJ
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):249-265. PubMed ID: 28613092
[TBL] [Abstract][Full Text] [Related]
18. Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model.
Dolk C; Eichner M; Welte R; Anastassopoulou A; Van Bellinghen LA; Poulsen Nautrup B; Van Vlaenderen I; Schmidt-Ott R; Schwehm M; Postma M
Pharmacoeconomics; 2016 Dec; 34(12):1299-1308. PubMed ID: 27647004
[TBL] [Abstract][Full Text] [Related]
19. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
van de Witte S; Nauta J; Montomoli E; Weckx J
Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program.
Zeevat F; Crépey P; Dolk FCK; Postma AJ; Breeveld-Dwarkasing VNA; Postma MJ
Value Health; 2021 Jan; 24(1):3-10. PubMed ID: 33431150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
